Lymaris Garcia Medina, MD
Pulmonary Disease · Hudson, NYNPI 1740508191
Payments from drug & device makers
Across 612 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Boehringer Ingelheim$945
- Sanofi$915
- Philips North America LLC$668
- Regeneron Healthcare Solutions, Inc.$626
- plus $3K from 33 others
What the payments were for
- Food & beverage$11,088100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 165 | $2,475 |
| AstraZeneca(2 entities) | 125 | $2,313 |
| Boehringer Ingelheim | 53 | $945 |
| Sanofi | 41 | $915 |
| Philips North America LLC | 35 | $668 |
| Regeneron Healthcare Solutions, Inc. | 28 | $626 |
| Grifols USA, LLC | 27 | $554 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $344 |
| Insmed, Inc. | 12 | $229 |
| Johnson & Johnson | 10 | $202 |
| Merck | 13 | $192 |
| Mallinckrodt Hospital Products Inc. | 10 | $179 |
| Pfizer | 9 | $167 |
| Mylan Specialty L.p. | 8 | $161 |
| Amgen | 6 | $129 |
| Actelion Pharmaceuticals US, Inc. | 5 | $126 |
| Verona Pharma, Inc. | 4 | $98 |
| Pulmonx Corporation | 3 | $91 |
| Jazz Pharmaceuticals Inc. | 5 | $88 |
| Novartis | 4 | $74 |
| United Therapeutics Corporation | 3 | $55 |
| Genentech USA, Inc. | 4 | $53 |
| Sunovion Pharmaceuticals Inc. | 6 | $52 |
| Paratek Pharmaceuticals, Inc. | 3 | $43 |
| Viatris Specialty LLC | 2 | $39 |
| Optinose US, Inc. | 2 | $34 |
| Inogen, Inc. | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $25 |
| AbbVie | 1 | $24 |
| Shire North American Group Inc | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Gilead | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Circassia Inc. | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $11 |
How this compares
$11,099 in reported general payments places this provider in the 80th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 341 | $306,822 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 139 | $128,202 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 126 | $87,904 |
| Breo ElliptaFluticasone/Vilanterol | 110 | $77,832 |
| Dupixent SyringeDupilumab | 15 | $57,182 |
| Spiriva RespimatTiotropium Bromide | 53 | $54,248 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 78 | $52,394 |
| Incruse ElliptaUmeclidinium Bromide | 61 | $35,910 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 40 | $35,086 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 717 | $31,587 |
| SymbicortBudesonide/Formoterol Fumarate | 71 | $21,047 |
| Advair HfaFluticasone Propion/Salmeterol | 35 | $18,854 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 86 | $18,582 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 25 | $16,184 |
| Arnuity ElliptaFluticasone Furoate | 30 | $10,802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,475 | $519,270668 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,313 | $165,433235 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $945 | $141,728171 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $14 | $8,00219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Hudson
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.